47
Participants
Start Date
March 31, 2011
Primary Completion Date
February 4, 2019
Study Completion Date
February 4, 2019
bortezomib (Velcade)
1.3 mg/m2 IVP on days 1, 4, 8 and 11
cyclophosphamide
2.0 g/m2 (day 4 for Arm A and day 1 for Arm C)
G-CSF
given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day (start on day 2 for Arm C and start on Day 1 for Arm D)
Plerixafor
plerixafor is given on day 4, approximately 11 hours prior to stem cell collection attempt on Day 5, plerixafor daily until stem cell collection is complete (Arm D), start on Day 12, approximately 11 hours prior to stem cell collection attempt and plerixafor daily until collection if complete (Arm E)
New York University Cancer Institute, New York
Columbia Presbyterian Medical Center):, New York
Memorial Sloan-Kettering Cancer Center):, New York
Weill Cornell Medical College, New York
Emory University, Atlanta
Collaborators (1)
Millennium Pharmaceuticals, Inc.
INDUSTRY
Weill Medical College of Cornell University
OTHER